Business Description
Nuvation Bio Inc
NAICS : 541713
SIC : 2834
1500 Broadway, Suite 1401, New York, NY, USA, 10036
Description
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 264.88 | |||||
| Equity-to-Asset | 0.96 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | 0 | |||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.47 | |||||
| 9-Day RSI | 31.09 | |||||
| 14-Day RSI | 32.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 34.89 | |||||
| Quick Ratio | 34.89 | |||||
| Cash Ratio | 34.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -11.44 | |||||
| ROA % | -11.04 | |||||
| ROIC % | -2658.94 | |||||
| ROC (Joel Greenblatt) % | -5469.41 | |||||
| ROCE % | -13.04 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.75 | |||||
| Price-to-Tangible-Book | 0.75 | |||||
| EV-to-EBIT | 1.88 | |||||
| EV-to-Forward-EBIT | -0.12 | |||||
| EV-to-EBITDA | 1.89 | |||||
| EV-to-FCF | 2.44 | |||||
| Price-to-Net-Current-Asset-Value | 0.75 | |||||
| Price-to-Net-Cash | 0.77 | |||||
| Earnings Yield (Greenblatt) % | 53.19 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NYSE:NUVB
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -0.42 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 32.68 | ||
| 14-Day ATR ($) | 0.235728 | ||
| 20-Day SMA ($) | 3.083 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 2.25 - 6.02 | ||
| Shares Outstanding (Mil) | 218.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nuvation Bio Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||